EMEA-000574-PIP02-12-M03
Key facts
| Invented name |
Blincyto
|
| Active substance |
blinatumomab
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0143/2020
|
| PIP number |
EMEA-000574-PIP02-12-M03
|
| Pharmaceutical form(s) |
Powder for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of acute lymphoblastic leukaemia
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Amgen Europe B.V.
E-mail: medinfointernational@amgen.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|